NCT06680258 - A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy | Biotech Hunter

Enrollment

740

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

July 31, 2030

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG

TPST-1120

TPST-1120 is an orally administered competitive antagonist of peroxisome proliferator-activated receptor α (PPARα)

BIOLOGICAL

Atezolizumab

Atezolizumab is an IV administered biologic.

BIOLOGICAL

Bevacizumab

Bevacizumab is an IV administered biologic.